Key Highlights
- In the 7MM, the highest prevalent cases of Hemophilia A were in the United States, accounting for nearly 14,300 cases in 2023.
- In Japan, the total prevalent population of Hemophilia A is nearly 5,600 in 2023 and is anticipated to rise during the forecast period.
- In the US, Hemophilia A contributed nearly 80% of overall Hemophilia.
- In 2023, the prevalent cases of mild Hemophilia A in the United States were identified to be 3,600, moderate as 2,900, and severe as 7,900.
- In the US, the prevalent cases of Hemophilia A were highest among the age group 19-44 years, and the least were between 0 and 4 years in 2023.
Geography Covered
- The United States
- EU4 (Germany, France, Italy, and Spain) and the United Kingdom
- Japan
Study Period: 2020-2034
Hemophilia A Disease Understanding
Hemophilia A Overview
Hemophilia A is a genetic bleeding disorder in which an individual lacks or has low levels of proteins named clotting factor VIII. The mainstay treatment option has long been FVIII replacement therapy. Initially, FVIII replacement was accomplished by donating whole blood, subsequently by plasma, and currently by recombinant human FVIII (rFVIII) replacement therapies, which revolutionized the treatment of Hemophilia A. Although hemophilia is usually diagnosed at birth, the disorder can also be acquired later in life if the body begins to produce antibodies that attack and destroy clotting factors. However, this acquired type of hemophilia is very rare.Hemophilia A Diagnosis
The symptoms of Hemophilia A can vary greatly from one person to another; it ranges from mild to moderate to severe. The age of onset and frequency of bleeding episodes depend upon the amount of factor VIII protein and the overall clotting ability of the blood. In most individuals, regardless of severity, bleeding episodes tend to be more frequent in childhood and adolescence than in adulthood.Additionally, the diagnosis of Hemophilia A depends on the identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation, and a variety of specialized laboratory tests. The identification of a hemizygous F8 pathogenic variant on molecular genetic testing in a male proband confirms the diagnosis.
Hemophilia A Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of Hemophilia A, age-specific prevalent cases of Hemophilia A, severity-specific prevalent cases of Hemophilia A, prevalent cases of Hemophilia A with or without Inhibitors and treated pool of Hemophilia A in the 7MM market covering the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan from 2020 to 2034.- The total prevalent population of Hemophilia A in the 7MM comprised 45,500 cases in 2023 and is projected to increase during the forecast period.
- The total prevalent population of Hemophilia A in the United States is ~14,300 in 2023.
- The United States contributed to the largest prevalent population of Hemophilia A, accounting for ~30% of the 7MM in 2023.
- In EU4 and the UK, the diagnosed prevalence of Hemophilia A was found to be maximum in France, followed by the UK. While the least number of cases were found in Spain in 2023.
- In Japan, the total prevalent population of Hemophilia A was ~5,600 in 2023 and is anticipated to rise during the forecast period.
- In 2023, the prevalent cases of mild Hemophilia A in the United States were identified to be ~3,600, moderate as ~2,900, and severe as ~7,900.
- In the US, ~2,400 cases accounted for inhibitors and ~12,000 cases for non-inhibitor in 2023.
Scope of the Report
- The report covers a segment of an executive summary and descriptive overview of Hemophilia A, explaining its causes, signs and symptoms, pathogenesis, and diagnostic approaches.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression.
- A detailed review of the Hemophilia A epidemiology, detailed assumptions, and rationale behind our approach is included in the report.
- A detailed review of current challenges in establishing the diagnosis.
Report Insights
- Patient Population
- Country-wise Epidemiology Distribution
Report Key Strengths
- 11 Year Forecast
- 7MM Coverage
- Hemophilia A Epidemiology Segmentation
Report Assessment
- Epidemiology Segmentation
- Current Diagnostic Practices
Key Questions
- What are the disease risk, burden, and unmet needs of Hemophilia A? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Hemophilia A?
- What is the historical Hemophilia A patient pool in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
- What would be the forecasted patient pool of Hemophilia A at the 7MM level?
- Out of the above-mentioned countries, which country would have the highest prevalent population of Hemophilia A during the study period (2020-2034)?
- At what CAGR is the population expected to grow across the 7MM during the study period (2020-2034)?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the Hemophilia A market.
- To understand the future market competition in the Hemophilia A market and an insightful review of the key market drivers and barriers.
- Quantify patient populations in the global Hemophilia A market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the best opportunities for Hemophilia A in the US, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.
- The Hemophilia A Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and highlights disease trends over an 11-year forecast period using reputable sources.
Table of Contents
1. Key Insights2. Report Introduction4. Executive Summary of Esophageal Cancer6. Epidemiology Methodology9. Publisher Capabilities10. Disclaimer
3. Esophageal Cancer Market Overview at a Glance
5. Disease Background and Overview
7. Epidemiology and Patient Population
8. Appendix
List of Tables
List of Figures
